Koya Medical

What Koya Medical does

Koya Medical is a private medical device company founded in 2018 that develops Dayspring, an FDA-cleared non-pneumatic active compression system for treating lymphedema, phlebolymphedema, chronic venous insufficiency, lipedema, and related chronic edema conditions. Dayspring uses proprietary FlexFrame technology — electrically actuated frames embedded in a low-profile breathable garment that contract and relax horizontally to deliver gradient sequential compression and promote fluid drainage — combined with an inelastic static compression layer, a rechargeable handheld controller, and a mobile app for treatment programming and adherence tracking. The system is the first FDA-cleared mobility-enabled active compression device and is prescription-only durable medical equipment (DME), sold through healthcare providers and reimbursed via Medicare, commercial insurance, and a Veterans Affairs Federal Supply Schedule contract (July 2024–July 2029).

The company has raised approximately $67 million across a $11 million Series A (January 2021, led by Arboretum Ventures), a $26 million Series B (February 2022, led by 3x5 Partners with Asahi Kasei Ventures), and a financing round of up to $30 million led by OrbiMed in November 2023. Koya reports more than 14,950 patients treated with Dayspring, employs 100+ associates split between its Dallas, TX headquarters and Oakland, CA advanced research facility, and has secured FDA 510(k) clearance plus dedicated CMS HCPCS reimbursement codes for both upper and lower extremity indications. Clinical differentiation is anchored by the NILE (2022) and TEAYS (2024) randomized trials published in the Journal of Vascular Surgery, demonstrating 4× edema reduction and 44% higher treatment adherence versus pneumatic compression, and culminating in a 2026 multi-society position statement from the American Venous Forum and American Venous and Lymphatic Society endorsing non-pneumatic compression. The pipeline includes TissueIQ (a preclinical multi-modal tissue analyzer for early lymphedema detection), K9 (minimally invasive CVI ablation), and K1 (endovascular intervention for chronic DVT complications).

Revenue is generated primarily through Dayspring hardware sales via three channels: enterprise field sales to physicians, therapists, and healthcare systems; direct-to-patient education and prescription routing; and a dedicated Veterans Affairs program. Pricing is not publicly disclosed, and Koya reports no revenue figure. The company markets Dayspring through a multi-channel approach spanning clinical publications, patient testimonials, professional education, social media, and investor conferences, with reimbursement and coding support as a critical commercial enabler.

Name

Koya Medical

Legal name

Koya Medical, Inc.

Website

https://koyamedical.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Short description

Koya Medical is a private medical device company that develops Dayspring, an FDA-cleared non-pneumatic active compression system for treating lymphedema and venous diseases, sold as prescription DME via healthcare providers and reimbursed through Medicare, commercial insurance, and a Veterans Affairs supply contract.

Ownership category

akta.pro rank

Product category

Medical Compression Therapy Devices

NAICS

Software Publishers (5132)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Compression Therapy & Lymphedema DME (Garments, Pneumatic Pumps) (HLAHAMAH)

akta.pro secondary industry

Compression Therapy for Venous/Lymphedema (Bandages, Wraps, Garments) (HLAHALAF)

Keywords

• Medical compression devices
• Lymphedema treatment systems
• Vascular health solutions
• Active compression therapy
• Durable medical equipment

Headquarters

HQ city

Oakland

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations, Others

Revenue model

1. Dayspring Device Sales: Koya Medical generates revenue through the sale of its Dayspring active compression system, a durable medical equipment (DME) device. The device is available by prescription and is reimbursed through Medicare and commercial insurance plans. CMS has issued HCPCS codes for Dayspring. The product is a prescription-only medical device sold to healthcare providers and patients.
2. VA/Federal Supply Schedule: Koya Medical sells directly to the Veterans Affairs (VA) system through their Federal Supply Schedule contract (Contract Period: July 15, 2024 – July 14, 2029). Provides dedicated end-to-end support including ordering for the Prosthetics Department, training, and patient assistance.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Koya Medical develops and sells the Dayspring system, an FDA-cleared, prescription-only, mobile non-pneumatic active compression system for treating lymphedema, phlebolymphedema, chronic venous insufficiency, and related chronic edema conditions. The system combines a static compression garment with proprietary FlexFrame technology powered by a handheld mobile controller, enabling patients to remain active and mobile during treatment. The company also markets related products and pipeline programs (TissueIQ, K9, K1) addressing the broader vascular and lymphatic disease continuum.

Product overview

Koya Medical offers Dayspring as its primary FDA-cleared product - a mobile non-pneumatic active compression system for treating lymphedema, phlebolymphedema, chronic venous insufficiency, and related conditions. The system combines a low-profile active garment made of soft breathable mesh using proprietary Flexframe technology, a smart rechargeable handheld controller, and a mobile app for custom treatment programming. Dayspring is unique as the first compression therapy designed to enable patient movement and mobility during treatment. The innovation pipeline includes TissueIQ (a multi-modal tissue analyzer for early lymphedema detection), K9 (a minimally invasive ablation solution for chronic venous insufficiency), and K1 (an endovascular intervention for DVT complications).

Differentiator

Problem solved

Functional benefit

Brands

• Dayspring: FDA-cleared wearable non-pneumatic compression treatment for lymphedema, phlebolymphedema, venous insufficiency, lipedema, and chronic edema. The first mobility-enabled active compression system for upper and lower extremities.
• TissueIQ
• K9
• K1

Products and services

• Dayspring FDA-cleared mobile non-pneumatic active compression system for treatment of chronic edema, lymphedema, phlebolymphedema, venous insufficiency, and related conditions. Combines static compression garment with active compression via proprietary FlexFrames powered by a mobile controller, enabling patient mobility during treatment. Available for upper and lower extremities and prescribed by healthcare providers with Medicare/commercial insurance reimbursement.
• TissueIQ Pipeline multi-modal analyzer designed to provide objective, real-time assessment of tissue changes beneath the skin for detecting early and progressive lymphedema-related changes, often before visible swelling occurs. Intended for healthcare professionals managing at-risk patients.
• K9 Pipeline development program providing a minimally invasive ablation solution for chronic venous insufficiency, aimed at improving patient experience and accessibility while maintaining clinical effectiveness.
• K1 Pipeline endovascular interventional development program focused on improving patient access and clinical outcomes for those suffering from chronic complications from deep vein thrombosis (DVT).

Quantifiable outcome

• 4X more edema reduction vs pneumatic compression in clinical trials
• +4 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• American Venous ForumcoreStrategic or Co-development Partner · 2 March 2026American Venous Forum endorsed a multi-society position statement published in the Journal of Vascular Surgery affirming the clinical value of non-pneumatic compression (NPCD) for lymphedema management, referencing Koya's Dayspring clinical evidence.
• American Venous and Lymphatic SocietycoreStrategic or Co-development Partner · 2 March 2026American Venous and Lymphatic Society endorsed the multi-society position statement supporting NPCD clinical utility for lymphedema treatment based on evidence from 11 clinical studies including two randomized head-to-head trials.
• Lymphatic Education & Research Network (LE&RN)minorGTM or Marketing Partner · 15 May 2022Koya Medical is a sponsor of LE&RN's Run/Walk to Fight Lymphatic Diseases event. The company supports lymphatic disease awareness and education efforts.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC1L3dVIH5LkhY6ekgyHu4kQ
• Facebookfacebook.com/koyamedicalinc
• LinkedInlinkedin.com/company/koyamedical
• Instagraminstagram.com/koyamedical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Koya Medical